ClinConnect ClinConnect Logo
Search / Trial NCT01403402

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

Launched by CURE CMD · Jul 26, 2011

Trial Information

Current as of June 28, 2025

Recruiting

Keywords

Congenital Muscular Dystrophy Congenital Myopathy Neuromuscular Diseases Musculoskeletal Diseases

ClinConnect Summary

The Congenital Muscle Disease Study, also known as CMDPROS, is a long-term research project aimed at understanding various types of congenital muscular dystrophy and related conditions. Over the next 10 years, researchers will collect information from patients and their families to track health outcomes and identify any side effects from treatments. By registering in the Congenital Muscle Disease International Registry (CMDIR) at www.cmdir.org, participants can help build a global database that will aid in raising awareness, improving care standards, and potentially leading to new treatments for these conditions.

To be eligible for this study, individuals must have specific types of congenital muscular dystrophy, congenital myopathy, or congenital myasthenic syndrome. Participants will be asked to fill out a survey and provide medical records related to their diagnosis and treatment. Importantly, there is no need to travel for this study, making it easier for families to participate. Your involvement can significantly contribute to the understanding and future management of these muscle diseases.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Alpha 7/Alpha 9 Integrin Related Myopathy Collagen VI Related Myopathy (Ullrich through Bethlem CMD) Alpha-Dystroglycan Related Muscular Dystrophy (Dystroglycanopathy, WWS, MEB, Fukuyama, FKRP, LGMD2I, LGMD2K, LGMD2M, LGMD2N, LGMD2O) Choline Kinase B Receptor Emery-Dreifuss Muscular Dystrophy (EDMD, LGMD1B, LMNA, Emerin, FHL1, SYNE1, SYNE2, TMEM43) LAMA2 Related Muscular Dystrophy (Laminin Alpha 2 related dystrophy/MDC1A/Merosin deficient) LMNA Related Muscular Dystrophy (Laminopathy/LaminA/C, L-CMD, Emery Dreifuss muscular dystrophy) RYR1 Related Myopathy (with dystrophic presentation, including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) SEPN1 Related Myopathy (Rigid Spine Muscular Dystrophy/RSMD1, Congenital Fiber Type Disproportion, Mallory Weiss Body Desmin, Multi-minicore Myopathy) SYNE1 (Nesprin Related Muscular Dystrophy) Telethonin Related Muscular Dystrophy (TCAP/Titin-Cap) Congenital Muscular Dystrophy Not Otherwise Specified (including Merosin Positive) Titin Related LGMD/CMD, LGMD2J Actin Aggregation Myopathy Cap Disease Central Core Disease (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Centronuclear Myopathy (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Congenital Fiber Type Disproportion (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Core Rod Myopathy Hyaline Body Myopathy Multiminicore Myopathy Myotubular Myopathy Nemaline Myopathy Reducing Body Myopathy RYR1 Related Myopathy (including Malignant Hyperthermia, Exertional Myalgia with or without Rhabdomyolysis) Spheroid Body Myopathy Titin Related Myopathy, Titin Related Dialated Cardiomyopathy, LGMD2J Tubular Aggregate Myopathy Zebra Body Disease Myopathy Congenital Myopathy Not Otherwise Specified Congenital Myasthenic Syndrome Escobar Syndrome Myofibrillar Myopathy
  • Exclusion Criteria:
  • Charcot Marie Tooth Duchenne/Becker Muscular Dystrophy Facioscapulohumeral Dystrophy/FSHD Kennedy's Disease LGMD-1A (TTID) LGMD-1C (CAV3, Caveloin 3, Caveolinopathy, LQT9, VIP21) LGMD-1D (7q) LGMD-1E (6q23) LGMD-1F (7q32.1-q32.2) LGMD-1G (4q21) LGMD-2A (CAPN3/Calpainopathy) LGMD-2B (DYSF/Dysferlinopathy/Miyoshi Myopathy) LGMD-2C (SGCG) LGMD-2D (SGCA) LGMD-2E (SGCB) LGMD-2F (SGCD) LGMD-2L (AN05/Anoctamin 5) Lipodystrophy Myotonic Dystrophy Oculopharyngeal Muscular Dystrophy Spinal Muscular Atrophy

About Cure Cmd

Cure CMD is a nonprofit organization dedicated to advancing research and developing innovative therapies for congenital muscular dystrophies (CMD). Through collaborative partnerships with academic institutions, industry leaders, and patient advocacy groups, Cure CMD focuses on accelerating the discovery of effective treatments and improving the quality of life for individuals affected by CMD. Their commitment to scientific rigor and patient-centered approaches drives a multifaceted agenda that includes funding research initiatives, fostering clinical trials, and enhancing awareness of this rare group of muscular disorders.

Locations

Lakewood, California, United States

Patients applied

0 patients applied

Trial Officials

Gustavo Dziewczapolski, PhD

Study Chair

CureCMD, CMDIR

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials